Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 699

Results For "US"

8050 News Found

Moderna Covid-19 boosters after five-month interval: U.S. FDA
News | January 08, 2022

Moderna Covid-19 boosters after five-month interval: U.S. FDA

Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older


Lilly and Entos  collaborate for therapies in multiple neurologic indications
Biotech | January 07, 2022

Lilly and Entos collaborate for therapies in multiple neurologic indications

Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly


Maharasthra Health Minister inaugurates BSV research centre at Airoli, Maharashtra
Biotech | January 07, 2022

Maharasthra Health Minister inaugurates BSV research centre at Airoli, Maharashtra

The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems


Pfizer and BioNTech to develop first mRNA-based Shingles vaccine
Biotech | January 07, 2022

Pfizer and BioNTech to develop first mRNA-based Shingles vaccine

Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022


SyneuRx oral Covid-19 anti-viral drug Pentarlandir shows promise against Delta and Omicron
Biotech | January 07, 2022

SyneuRx oral Covid-19 anti-viral drug Pentarlandir shows promise against Delta and Omicron

Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬


Lupin launches Molnulup to treat Covid-19
News | January 07, 2022

Lupin launches Molnulup to treat Covid-19

The drug is priced at Rs 2000 for a course of 40 tablets


AstraZeneca and Neurimmune to develop and commercialise NI006
Biotech | January 07, 2022

AstraZeneca and Neurimmune to develop and commercialise NI006

Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition


Merck KGaA to acquire biopharma CDMO Exelead for $780 million
Biotech | January 07, 2022

Merck KGaA to acquire biopharma CDMO Exelead for $780 million

The transaction is expected to close in the first quarter of 2022


Barentz appoints Daniel Hitz as CEO, APAC
People | January 07, 2022

Barentz appoints Daniel Hitz as CEO, APAC

Hitz shall assume new role from January 17th, 2022


NATHEALTH Home Care Forum launches white paper on healthcare delivery
Healthcare | January 06, 2022

NATHEALTH Home Care Forum launches white paper on healthcare delivery

10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies